Link boss George Hongchoy to retire in June
George Hongchoy, head of Hong Kong's real estate investment giant Link, says he'll work with the management to bring about a smooth transition. File photo: RTHK
Link Asset Management (Link) announced on Tuesday that its chief executive and executive director, George Hongchoy, plans to retire by the end of June 2026.
In a statement, the board of the company, Asia's largest real estate investment trust (REIT), also said it would search for a successor to Hongchoy to lead the company into the next phase of its development.
It expressed gratitude to Hongchoy for his contribution and leadership over the past 16 years.
"Under George's leadership over the past 16 years, Link has grown and transformed to the benefit of unitholders, tenants, employees and the wider communities that we serve," said chairman Duncan Owen.
"On behalf of the board and everyone at Link, I would like to express sincere gratitude to George for his significant contributions.
"We look forward to continuing to work together during the transition."
For his part, Hongchoy said he'll work with the leadership team to bring about a smooth transition.
'It has been a privilege and honour to serve as group CEO of Link during a formative period of the organisation's growth and development," he said.
"We have strengthened the overall leadership of the business in recent years, and I am confident we have the right team in place for the next phase of Link's development,' he added.
Link manages the Link REIT, which oversees some HK$226 billion in assets across the retail, office and logistics sectors, according to its website.
Hongchoy, a former investment banker, joined the company in 2009 as chief financial officer before moving to the top job the following year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RTHK
2 days ago
- RTHK
DSE candidates face 4pc rise in fees for 2026 exams
DSE candidates face 4pc rise in fees for 2026 exams The HKEAA says fees and charges are going up to optimise use of resources and maintain its long-term stability. File photo: RTHK The exams body on Friday announced a 4 percent increase in fees for the 2026 Hong Kong Diploma of Secondary Education (HKDSE) exams and the introduction of a new fees structure for private candidates. According to the Hong Kong Examinations and Assessment Authority (HKEAA), the fees for school candidates for key language and other subjects have been raised by HK$30 and HK$20 each respectively. For a candidate taking six subjects – two language and four other subjects – the total fees will amount to HK3,630. The HKEAA stated that the hike is similar to previous years and remains at a relatively moderate level, with the adjustment taking into account various factors. For private candidates, a flat fee of HK$595 will be charged and there will be a new two-tier fees structure depending on their residency status. Candidates who are non-Hong Kong permanent residents are required to pay HK$1,377 for each language subject and HK$1,119 for each additional subject, HK$600 more when compared with that for local residents. For non-permanent residents who are under 18 years old and sitting the exam for the first time, there will be a new special entry fee of HK$2,000 per person. That would mean examination fees of more than HK$9,800 for those taking four core subjects and two electives. The HKEAA said the fees and charges had been revised to optimise the use of resources and maintain the long-term financial stability of the body. "There has been a notable increase in the number of private candidates in recent years. Some of these candidates, holding non-HKDSE qualifications, are required to submit Special Entry applications, which necessitate substantial manpower and resources from the authority to carefully vet each case," it said. "Additional examination centres and personnel have also been arranged to accommodate the growing number of private candidates, further increasing the operational costs of the HKDSE."
South China Morning Post
3 days ago
- South China Morning Post
Pfizer, Chinese biotech firm 3SBio complete worldwide licensing deal for cancer drug
First announced in May, the deal will see 3SBio – based in Shenyang, capital of northeastern Liaoning province – receive a US$1.25 billion upfront payment from Pfizer for the exclusive right to sell its cancer drug, SSGJ-707, outside China. Under the terms of their agreement, Pfizer will also pay 3SBio up to US$150 million to solely develop and commercialise SSGJ-707 within the mainland, the two companies said on Thursday. Pfizer also agreed to buy 31.1 million new shares in S3Bio, or a 1.3 per cent equity stake, for HK$785 million, according to a stock exchange filing. The deal at HK$25.2055 per share represents a 17 per cent discount to its market price on Thursday. 3SBio's shares fell 6.41 per cent to HK$28.45 on Friday. The transaction reflected the strong momentum of Chinese biotech firms in the field of drugs research and the increased interest from major foreign pharmaceutical companies to license their intellectual property.
South China Morning Post
3 days ago
- South China Morning Post
Hong Kong life insurance sales jump 43% to record high in first quarter
Life insurance sales in Hong Kong rose 43 per cent in the first quarter to a record high on demand for protection and estate planning from high-net-worth customers and visitors from mainland China, as the city seeks to become a wealth management hub to rival global leaders like Switzerland. The industry wrote HK$93.4 billion (US$12 billion) worth of new life policies in the first quarter, up from HK$65.3 billion a year earlier, the Insurance Authority said on Friday. It was the highest first-quarter sales tally since the authority was established in 2016. Hong Kong had a record year in 2024, when insurers posted a 21.4 per cent jump in sales to HK$219.8 billion, courtesy of a world-record policy sold by HSBC Life. 'Hong Kong's insurance industry continued its strong momentum in early 2025, supported by sustained demand for savings, health, and protection products from both local customers and mainland Chinese visitors,' said Patrick Graham, CEO of Manulife Hong Kong and Macau. The regulator did not disclose policy sales to mainland visitors, having earlier decided to release such statistics after a review about the disclosures of non-local buyers.
